Proteomic characterization of human LMNA-related congenital muscular dystrophy muscle cells
Neuromuscular Disorders · 2024
DOI: 10.1016/j.nmd.2024.03.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuromuscular Disorders, 2024. Verfasst von Emily C Storey und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wolfson Centre for Inherited Neuromuscular Disease, RJAH Orthopaedic Hospital, Oswestry, SY10 7AG, UK; The School of Pharmacy and Bioengineering, Kee…. Hauptthemen laut MEDLINE: Lamin Type A, Proteomics, Muscular Dystrophies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council, Institute of Orthopaedics.
Abstract (Originalsprache)
LMNA-related congenital muscular dystrophy (L-CMD) is caused by mutations in the LMNA gene, encoding lamin A/C. To further understand the molecular mechanisms of L-CMD, proteomic profiling using DIA mass spectrometry was conducted on immortalized myoblasts and myotubes from controls and L-CMD donors each harbouring a different LMNA mutation (R249W, del.32 K and L380S). Compared to controls, 124 and 228 differentially abundant proteins were detected in L-CMD myoblasts and myotubes, respectively, and were associated with enriched canonical pathways including synaptogenesis and necroptosis in myoblasts, and Huntington's disease and insulin secretion in myotubes. Abnormal nuclear morphology and reduced lamin A/C and emerin abundance was evident in all L-CMD cell lines compared to controls, while nucleoplasmic aggregation of lamin A/C was restricted to del.32 K cells, and mislocalization of emerin was restricted to R249W cells. Abnormal nuclear morphology indicates loss of nuclear lamina integrity as a common feature of L-CMD, likely rendering muscle cells vulnerable to mechanically induced stress, while differences between L-CMD cell lines in emerin and lamin A localization suggests that some molecular alterations in L-CMD are mutation specific. Nonetheless, identifying common proteomic alterations and molecular pathways across all three L-CMD lines has highlighted potential targets for the development of non-mutation specific therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wolfson Centre for Inherited Neuromuscular Disease, RJAH Orthopaedic Hospital, Oswestry, SY10 7AG, UK; The School of Pharmacy and Bioengineering, Keele University, ST5 5BG, UK.
- BSRC Mass Spectrometry and Proteomics Facility, University of St Andrews, KY16 9ST, UK.
- Wolfson Centre for Inherited Neuromuscular Disease, RJAH Orthopaedic Hospital, Oswestry, SY10 7AG, UK; The School of Pharmacy and Bioengineering, Keele University, ST5 5BG, UK. Electronic address: h.r.fuller@keele.ac.uk.
Förderung
- Biotechnology and Biological Sciences Research Council
- Institute of Orthopaedics
Zitieren
APA
Storey, E. C., Holt, I., Brown, S., Synowsky, S., Shirran, S., & Fuller, H. R. (2024). Proteomic characterization of human LMNA-related congenital muscular dystrophy muscle cells. Neuromuscular Disorders. https://doi.org/10.1016/j.nmd.2024.03.006
Vancouver
Storey EC, Holt I, Brown S, Synowsky S, Shirran S, Fuller HR. Proteomic characterization of human LMNA-related congenital muscular dystrophy muscle cells. Neuromuscular Disorders. 2024. doi:10.1016/j.nmd.2024.03.006
BibTeX
@article{Storey2024,
author = {Storey, Emily C and Holt, Ian and Brown, Sharon and Synowsky, Silvia and Shirran, Sally and Fuller, Heidi R},
title = {Proteomic characterization of human LMNA-related congenital muscular dystrophy muscle cells},
journal = {Neuromuscular Disorders},
year = {2024},
doi = {10.1016/j.nmd.2024.03.006}
}
EUVIMED